South San Francisco, United States
Pragma Bio, founded in 2019 and headquartered in the United States, is carving a niche in the intersecting worlds of Analytics, Biotechnology, and Health and Wellness. Their slogan, "Mining the molecules that matter," succinctly captures their mission to demystify immunological disorders previously deemed undruggable.
By leveraging real-world data alongside synthetic biology, Pragma Bio aims to elucidate the complex biological signatures that influence clinical outcomes. This pioneering approach not only enhances understanding but also promises the production of natural compounds with undeniable therapeutic potential.
Recently, the company secured a Series A investment as of July 31, 2023. However, details regarding involved investors remain undisclosed. As an entity focusing on harnessing untapped biological molecules, Pragma Bio presents a compelling investment opportunity with its innovative methodologies and potential for high-impact healthcare solutions.
